Table 2.
HR and 95% CI on 3rd, 6th, 9th, 12th, 15th, 18th, 21st, and 24th month OS for immunotherapy combinations compared to placebo.
| Time (months) | Serp | Atez | Durv | Adeb | Nivo | Atez-Tira | Durv-Trem | Pemb | Ipi | Pla |
|---|---|---|---|---|---|---|---|---|---|---|
| 3rd | 1.29 (0.22,7.53) | 1.31 (0.23,7.65) | 1.04 (0.20,5.47) | – | 2.61 (0.43,15.98) | 1.36 (0.24,7.74) | – | – | – | Reference |
| 6th | 2.02 (1.24,3.30) | 1.34 (0.78,2.29) | 1.04 (0.68,1.60) | – | 1.74 (0.90,3.36) | 1.05 (0.61,1.79) | – | 1.07 (0.69,1.64) | 1.08 (0.78,1.48) | Reference |
| 9th | 1.72 (1.19,2.50) | 1.31 (0.87,1.96) | 1.42 (0.99,2.01) | 0.97 (0.63,1.47) | 3.00 (1.23,7.30) | 1.09 (0.71,1.67) | 1.06 (0.75,1.49) | 1.14 (0.79,1.65) | 1.04 (0.81,1.34) | Reference |
| 12th | 1.66 (1.18,2.36) | 1.60 (1.08,2.38) | 1.71 (1.21,2.40) | 1.66 (1.14,2.40) | 4.03 (1.26,12.84) | – | 1.17 (0.83,1.65) | 1.33 (0.92,1.94) | 1.17 (0.91,1.50) | Reference |
| 15th | 2.05 (1.44,2.92) | 1.97 (1.30,2.97) | 1.53 (1.07,2.18) | 1.58 (1.09,2.28) | 16.43 (0.92,292.62) | – | 1.19 (0.83,1.70) | 1.62 (1.09,2.41) | 1.18 (0.90,1.55) | Reference |
| 18th | 1.72 (1.20,2.47) | 1.90 (1.22,2.98) | 1.42 (0.98,2.08) | 1.95 (1.32,2.87) | – | – | 1.37 (0.94,2.00) | 1.49 (0.97,2.27) | 1.22 (0.89,1.67) | Reference |
| 21st | 6.28 (3.68,10.73) | 1.52 (0.89,2.59) | 1.43 (0.90,2.29) | 1.97 (1.22,3.17) | – | – | 1.42 (0.89,2.27) | 1.87 (1.10,3.18) | 1.19 (0.53,2.67) | Reference |
| 24th | 6.09 (0.68,54.14) | 1.38 (0.15,12.28) | 1.83 (0.21,16.16) | 2.19 (0.25,19.27) | – | – | 1.80 (0.20,15.84) | 2.35 (0.26,21.16) | 2.66 (0.26,27.37) | Reference |
Nivo, nivolumab; Atez-Tira, tiragolumab; Atez, atezolizumab; Serp, serplulimab; Durv, Durvalumab; Durv-Trem, Durvalumab + tremelimumab; Pla, Placebo; Adeb, Adebrelimab; Pemb, Pembrolizumab; Ipi, ipilimumab.Significant results were in bold.